DHR vs CDXS vs RVTY Stock Comparison

Danaher, Codexis and Revvity Prices as of Oct 28, 2026 Peers: Industry group
DHR Danaher Corp /De/
$234.09 +2.9% 1M +7.9% 1Y
Market cap
$167.09B
P/E
41.7x
Revenue (TTM)
$25.11B
Div. yield
–
Life Sciences Tools Healthcare
7 wins
CDXS Codexis, Inc.
$1.26 -7.4% 1M -51.4% 1Y
Market cap
$110.63M
P/E
–
Revenue (TTM)
$77.68M
Div. yield
–
Life Sciences Tools Healthcare
2 wins
RVTY Revvity, Inc.
$165.36 +9.5% 1M +71.4% 1Y
Market cap
$18.46B
P/E
77.7x
Revenue (TTM)
$2.91B
Div. yield
0.00%
Life Sciences Tools Healthcare
2 wins

Head to Head

11 decided of 12

Danaher leads on 7 of the 12 questions below (Danaher 7, Codexis 2, Revvity 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionDHRCDXSRVTYLeader
Larger companyMarket capitalisation $167.09B $110.63M $18.46B DHR
Cheaper on earningsLower P/E, profitable companies only 41.7x -3.6x 77.7x DHR
Cheaper on forward earningsLower price / next fiscal year consensus EPS 25.7x — 32.4x DHR
Faster revenue growthRevenue growth, trailing twelve months +4.6% +35.9% +4.1% CDXS
More profitableNet margin, trailing twelve months 15.9% -39.6% 8.2% DHR
Better return on capitalReturn on invested capital 5.7% -35.1% 3.1% DHR
Less leveragedLower net debt / EBITDA 2.9x 0.7x 2.8x CDXS
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +7.9% -51.4% +71.4% RVTY
Better 5-year returnAnnualised price return, 5 years -5.6%/yr -48.5%/yr -1.3%/yr RVTY
Less volatileAnnualised volatility, 1 year 30.6% 86.7% 39.9% DHR
Higher overall scoreMean of the five percentile scores vs peers 60/100 44/100 58/100 DHR

Percentile Scorecard

DHRCDXSRVTY

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisDHRCDXSRVTY
Valuation 69 #72 of 227 41 #134 of 227 68 #74 of 227
Growth 22 #172 of 219 66 #75 of 219 28 #158 of 219
Profitability 88 #26 of 205 44 #116 of 205 80 #41 of 205
Financial Health 46 #129 of 237 30 #166 of 237 47 #127 of 237
Shareholder Returns 75 #34 of 135 40 #81 of 135 66 #46 of 135
Overall 60 44 58
  • DHR ranked among 247 companies in Medical Devices and Diagnostics
  • CDXS ranked among 247 companies in Medical Devices and Diagnostics
  • RVTY ranked among 247 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodDHRCDXSRVTYSPY
1 month +2.9%-7.4%+9.5% +0.9%
3 months +19.1%-14.3%+45.8% +5.9%
6 months +30.9%-55.2%+101.0% +8.5%
Year to date +2.3%-22.7%+70.9% +13.3%
1 year +7.9%-51.4%+71.4% +12.4%
3 years +24.6%-18.7%+69.0% +88.1%
3 years, per year +7.6%-6.7%+19.1% +23.5%
5 years -24.9%-96.4%-6.5% +68.2%
5 years, per year -5.6%-48.5%-1.3% +11.0%
10 years +199.4%-72.0%+225.5% +263.4%
10 years, per year +11.6%-12.0%+12.5% +13.8%

Risk

MeasureDHRCDXSRVTYSPY
Volatility, 1Y 30.6%86.7%39.9% 12.7%
Downside volatility, 1Y 31.7%91.1%35.9% 12.7%
Beta vs S&P 500, 1Y 0.451.851.23 1.00
Return / volatility, 1Y 0.26-0.591.79 0.98
Max drawdown, 5Y -50.8%-97.7%-59.2% -25.4%
From 52-week high -3.3%-55.8%0.0% -0.9%
52-week high $242.05$2.85$165.36 $779.14
52-week low $161.91$0.98$82.26 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleDHRCDXSRVTY
P/E now vs peer median 41.2xmedian 28.8x -3.7xmedian 28.8x 77.7xmedian 28.8x
P/S now vs peer median 6.6xmedian 3.0x 1.5xmedian 3.0x 6.3xmedian 3.0x
EV/EBITDA now vs peer median 24.4xmedian 17.4x -4.8xmedian 17.4x 26.6xmedian 17.4x
P/FCF now vs peer median 30.1xmedian 25.7x -9.5xmedian 25.7x 32.4xmedian 25.7x
P/B now vs peer median 3.1xmedian 2.4x 3.5xmedian 2.4x 2.6xmedian 2.4x
PEG now vs peer median -3.29median 1.03 -0.14median 1.03 -2.49median 1.03

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsDHRCDXSRVTY
Revenue $25.11B $77.68M $2.91B
Gross profit $14.69B $67.60M $1.60B
Operating income $5.13B -$27.66M $358.85M
Net income $4.00B -$30.72M $237.55M
Free cash flow $5.47B -$12.18M $568.85M
R&D $1.62B $48.74M $215.83M
EPS (diluted) $5.66 $-0.34 $2.13
Cash & equivalents $4.35B $27.17M $1.02B
Total debt $26.56B $40.88M $3.21B
Shares (diluted) 707.60M 91.05M 111.63M
Enterprise value $150.90B -$146.42M $14.73B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricDHRCDXSRVTY
P/E 41.2x -3.7x 77.7x
P/FCF 30.1x -9.5x 32.4x
P/Operating cash flow 24.8x -11.1x 28.9x
P/S 6.6x 1.5x 6.3x
P/B 3.1x 3.5x 2.6x
P/Tangible book 5.3x 3.5x 3.7x
EV/EBITDA 24.4x -4.8x 26.6x
EV/EBIT 36.4x -3.7x 57.5x
EV/Revenue 7.4x 1.3x 7.1x
EV/FCF 34.2x -8.3x 36.3x
EV/Operating cash flow 28.1x -9.7x 32.3x
PEG (3Y EPS CAGR) -3.29 -0.14 -2.49

Growth

14 metrics
MetricDHRCDXSRVTY
Revenue growth (1Y) 4.6% 35.9% 4.1%
Revenue CAGR (3Y) -0.5% -7.8% 0.9%
Gross profit growth (1Y) 2.6% 52.4% 2.3%
Gross profit CAGR (3Y) -0.9% -2.6% -0.4%
Operating income growth (1Y) 16.1% 51.7% -5.5%
Operating income CAGR (3Y) -7.1% 22.8% -3.7%
Net income growth (1Y) 17.3% 52.7% -16.7%
Net income CAGR (3Y) -14.3% 18.5% -33.8%
EPS growth (1Y) 19.2% 55.7% -12.3%
EPS CAGR (3Y) -12.5% 26.2% -31.2%
Operating cash flow growth (1Y) 7.6% 83.0% 6.2%
Operating cash flow CAGR (3Y) -7.6% -152.3% 86.9%
Free cash flow growth (1Y) 12.4% 82.0% 9.5%
Free cash flow CAGR (3Y) -9.0% -26.3% 64.8%

Profitability

14 metrics
MetricDHRCDXSRVTY
Gross margin 58.5% 87.0% 55.0%
EBITDA margin 30.5% -27.0% 26.6%
Operating margin 20.4% -35.6% 12.3%
Pretax margin 19.0% -39.5% 9.0%
Net margin 15.9% -39.6% 8.2%
FCF margin 21.8% -15.7% 19.5%
Operating cash flow margin 26.4% -13.4% 21.9%
Return on equity 7.6% -80.6% 3.3%
Return on assets 4.5% -24.6% 2.0%
Return on invested capital 5.7% -35.1% 3.1%
Return on capital employed 6.4% -27.3% 3.3%
Asset turnover 0.3x 0.6x 0.2x
Cash conversion (OCF / net income) 1.7x 0.3x 2.7x
Stock comp / revenue 1.2% 9.9% 0.8%

Financial Health

11 metrics
MetricDHRCDXSRVTY
Debt / assets 28.8% 34.0% 26.6%
Debt / equity 0.5x 1.2x 0.4x
Net debt / EBITDA 2.9x 0.7x 2.8x
Debt / FCF 4.9x -3.4x 5.6x
Liabilities / assets 43.1% 72.5% 40.0%
Equity / assets 56.9% 27.5% 60.0%
Interest coverage 17.6x – 3.7x
Current ratio 1.7x 3.1x 1.8x
Quick ratio 1.0x 2.9x 1.4x
Cash ratio 0.5x 2.3x 0.8x
Altman Z-score 3.74 -6.15 3.45

Shareholder Returns

7 metrics
MetricDHRCDXSRVTY
Dividend yield 0.6% – 0.2%
Net buyback yield 1.8% -0.3% 2.5%
Shareholder yield 2.4% -0.3% 2.7%
Payout ratio (earnings) – – 13.4%
Payout ratio (FCF) – – 5.6%
Dividend growth (1Y) – – -6.3%
Dividend CAGR (3Y) – – -6.1%

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusDHRCDXSRVTY
Forward P/E 25.7xFY2026 – 32.4xFY2026
EPS, next fiscal year $9.11FY2026 $-0.37FY2026 $5.10FY2026
EPS growth, next FY +16.8%FY2026 – +0.8%FY2026
EPS growth, the year after +8.0% – +11.0%
Revenue, next fiscal year $27.01BFY2026 $77.93MFY2026 $2.98BFY2026
Revenue growth, next FY +9.9%FY2026 +10.7%FY2026 +4.0%FY2026
Revenue growth, the year after -1.9% +9.2% -2.0%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersDHRCDXSRVTY
Held by institutions 81.9% 71.0% 100.0%
Institutions holding 2,117 148 545
Change in shares held, QoQ +1.1% -2.4% -1.3%
Institutions buying 839 88 301
Institutions selling 1,015 36 161
Buyers to sellers 0.83 2.44 1.87

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

DHRCDXSRVTY
DHR 1.00 0.06 0.52
CDXS 0.06 1.00 0.09
RVTY 0.52 0.09 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, DHR, CDXS and RVTY?

Danaher (DHR) is the largest by market capitalisation: Danaher (DHR) $167.09B, Codexis (CDXS) $110.63M, Revvity (RVTY) $18.46B.

Which stock is cheaper, DHR, CDXS and RVTY?

Danaher (DHR) trades on the lowest price-to-earnings ratio (Danaher (DHR) 41.7x, Codexis (CDXS) -3.6x, Revvity (RVTY) 77.7x). On next year's consensus earnings, Danaher (DHR) is cheapest (Danaher (DHR) 25.7x, Revvity (RVTY) 32.4x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Codexis (CDXS) grew revenue fastest over the trailing twelve months: Danaher (DHR) +4.6%, Codexis (CDXS) +35.9%, Revvity (RVTY) +4.1%.

Which company is more profitable?

Danaher (DHR) has the highest net margin (Danaher (DHR) 15.9%, Codexis (CDXS) -39.6%, Revvity (RVTY) 8.2%). On return on invested capital, Danaher (DHR) leads (Danaher (DHR) 5.7%, Codexis (CDXS) -35.1%, Revvity (RVTY) 3.1%).

Which stock has performed better?

Over the past year Revvity (RVTY) returned the most: Danaher (DHR) +7.9%, Codexis (CDXS) -51.4%, Revvity (RVTY) +71.4%. Over five years, Revvity (RVTY) compounded fastest (Danaher (DHR) -5.6%/yr, Codexis (CDXS) -48.5%/yr, Revvity (RVTY) -1.3%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Danaher (DHR) 0.00%, Codexis (CDXS) 0.00%, Revvity (RVTY) 0.00%. Danaher (DHR) and Codexis (CDXS) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Danaher (DHR) has been the steadiest (Danaher (DHR) 30.6%, Codexis (CDXS) 86.7%, Revvity (RVTY) 39.9%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, DHR, CDXS and RVTY?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Danaher (DHR) leads on 7. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.